External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

HealthCare Global Enterprises / Equity Bottom-Up

<ul><li>Inline Revenue Performance: HCG delivered revenues broadly in line with expectations, growing a steady 13.3% YoY, supported by healthy performance across all centres; however, AP was disrupted due to temporary strikes related to a state-sponsored scheme.</li><li>Margin Performance: The company reported an EBITDA margin of 17.5%, an expansion of 150 bps YoY but a 175 bps QoQ decline.</li><li>EBITDA stood at Rs 110 Cr, up 24% YoY and 14.4% QoQ. Reported PAT was a loss of Rs 7.9 Cr, impacted by changes in labour codes.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Inline Revenue Performance: HCG delivered revenues broadly in line with expectations, growing a steady 13.3% YoY, supported by healthy performance across all centres; however, AP was disrupted due to temporary strikes related to a state-sponsored scheme.Margin Performance: The company reported an EBITDA margin of 17.5%, an expansion of 150 bps YoY but a 175 bps QoQ decline.EBITDA stood at Rs 110 Cr, up 24% YoY and 14.4% QoQ. Reported PAT was a loss of Rs 7.9 Cr, impacted by changes in labour codes.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Healthcare Global Enterprises Ltd - Guiding Steady Growth Ahead